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A new GWAS and meta-analysis 
with 1000Genomes imputation 
identifies novel risk variants for 
colorectal cancer
Nada A. Al-Tassan1,*, Nicola Whiffin2,*, Fay J. Hosking2,†, Claire Palles3, 
Susan M. Farrington4, Sara E. Dobbins2, Rebecca Harris5, Maggie Gorman3, Albert Tenesa4,6, 
Brian F. Meyer1, Salma M. Wakil1, Ben Kinnersley2, Harry Campbell7, Lynn Martin3, 
Christopher G. Smith5, Shelley Idziaszczyk5, Ella Barclay3, Timothy S. Maughan8, 
Richard Kaplan9, Rachel Kerr10, David Kerr11, Daniel D. Buchannan12,13, Aung Ko 
Win13, John Hopper13, Mark Jenkins13, Noralane M. Lindor14, Polly A. Newcomb15, 
Steve Gallinger16, David Conti17, Fred Schumacher17, Graham Casey17, Malcolm G. Dunlop4,†, 
Ian P. Tomlinson3,†, Jeremy P. Cheadle5,† & Richard S. Houlston2,†
Genome-wide association studies (GWAS) of colorectal cancer (CRC) have identified 23 susceptibility 
loci thus far. Analyses of previously conducted GWAS indicate additional risk loci are yet to be 
discovered. To identify novel CRC susceptibility loci, we conducted a new GWAS and performed 
a meta-analysis with five published GWAS (totalling 7,577 cases and 9,979 controls of European 
ancestry), imputing genotypes utilising the 1000 Genomes Project. The combined analysis identified 
new, significant associations with CRC at 1p36.2 marked by rs72647484 (minor allele frequency 
[MAF] = 0.09) near CDC42 and WNT4 (P = 1.21 × 10−8, odds ratio [OR] = 1.21 ) and at 16q24.1 
marked by rs16941835 (MAF = 0.21, P = 5.06 × 10−8; OR = 1.15) within the long non-coding RNA 
(lncRNA) RP11-58A18.1 and ~500 kb from the nearest coding gene FOXL1. Additionally we identified 
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a promising association at 10p13 with rs10904849 intronic to CUBN (MAF = 0.32, P = 7.01 × 10-8; 
OR = 1.14). These findings provide further insights into the genetic and biological basis of inherited 
genetic susceptibility to CRC. Additionally, our analysis further demonstrates that imputation can be 
used to exploit GWAS data to identify novel disease-causing variants.
Twin studies indicate that heritable factors account for 35% of the variation in risk of developing colorec-
tal cancer (CRC)1. However, only 5% of CRC can be attributed to the inheritance of high-penetrance 
mutations in the known genes2,3. Genome-wide association studies (GWAS) conducted primarily in 
European4–12 but also Asian13–16 populations have vindicated the long-held belief that part of the heritable 
risk of CRC is attributable to common, low-risk variants. These GWAS have provided insights into the 
biological basis of CRC, highlighting the role of genes within the bone morphogenetic protein signalling 
pathway (BMP2, BMP4, GREM1 and SMAD7)4,11 and some candidate genes (e.g. CDH1/CDH3), as well 
as genes not previously implicated in CRC (e.g. POLD3, TERC, CDKN1A and SHROOM2)5,6.
Despite the success of GWAS the risk SNPs so far identified in European populations account for 
only 8% of the familial CRC risk (Supplementary Table 1). Together with the over-representation of 
association signals in GWAS strongly suggests that additional risk SNPs remain to be discovered. The 
statistical power of individual GWAS is limited by the modest effect sizes of the genetic variants and the 
requirement for a stringent threshold to establish statistical significance in order to avoid type 1 errors. 
Meta-analysis of GWAS data therefore offers the opportunity to identify new CRC risk loci and provide 
further insights into tumour biology. Furthermore, imputation of untyped variants in GWAS data using 
publicly available reference datasets increases the number of variants that can be tested for an association 
with CRC risk.
To identify new CRC susceptibility loci, we conducted an independent primary scan of CRC using 
patient samples from the COIN trial and performed a genome-wide meta-analysis with five previously 
published GWAS. To recover untyped genotypes, thereby maximising the prospects of identifying risk 
variants, we imputed over 10 million SNPs in the six GWAS datasets, using data from the 1000 Genomes 
Project17 as reference (see Materials & Methods for details).
Methods
Primary GWAS. The COIN GWAS was based on 2,244 CRC cases (64% male, mean age 61 years, 
SD = 10) ascertained through two independent Medical Research Council clinical trials of advanced/
metastatic CRC; COIN and COIN-B18. Cases were genotyped using Affymetrix Axiom Arrays accord-
ing to the manufacturer’s recommendations (Affymetrix, Santa Clara, CA 95051, USA), using duplicate 
samples and sequencing of significantly associated SNPs in a subset of samples to confirm genotyping 
accuracy. For all SNPs > 99% concordant results were obtained. For controls, we made use of Wellcome 
Trust Case Control Consortium 2 (WTCCC2) Affymetrix 6.0 array data on 2,674 individuals from the 
UK Blood Service Control Group. Individuals were excluded with: < 95% successfully genotyped SNPs 
(n = 122), discordant sex information (n = 8), classed as out of bounds by Affymetrix (n = 30), duplica-
tion or cryptic relatedness (identity by descent > 0.185, n = 4), evidence of non-white European ancestry 
using PCA in conjunction with HapMap samples (n = 130; cut-off based on the minimum and maximum 
values of the top two principal components of the controls; Supplementary Figure 2). The details of all 
sample exclusions are provided in Supplementary Figure 3. We excluded SNPs from the analysis with: 
call rate <95%; different missing genotype rate between cases and controls at P < 10−5; MAF < 0.01; 
departure from Hardy–Weinberg equilibrium in controls at P < 10−5. The adequacy of the case–con-
trol matching and the possibility of differential genotyping of cases and controls were assessed using 
quantile-quantile (Q–Q) plots of test statistics.
Published GWAS. We made use of five published and previously described GWAS (see Supplementary 
Methods):. UK1 (CORGI)6 comprised 940 cases with colorectal neoplasia, Scotland1 (COGS)6 included 
1,012 CRC cases and 1,012 cancer-free population controls, VQ58 comprised 1800 CRC cases19 and 
2,690 population control genotypes from the WTCCC2 1958 birth cohort20, CCFR1 comprised 1,290 
familial CRC cases and 1,055 controls21, CCFR2 included a further 796 cases and 2,236 controls from the 
Cancer Genetic Markers of Susceptibility (CGEMS) studies of breast and prostate cancer22,23.
The VQ, UK1 and Scotland1 GWA cohorts were genotyped using Illumina Hap300, Hap240S, Hap370, 
Hap550 or Omni2.5M arrays. 1958BC genotyping was performed as part of the WTCCC2 study on 
Hap1.2M-Duo Custom arrays. The CCFR samples were genotyped using Illumina Hap1M, Hap1M-Duo 
or Omni-express arrays. CGEMS samples were genotyped using Illumina Hap300 and Hap240 or Hap550 
arrays. After applying the same quality control as that performed for COIN and COIN-B, data on 7,577 
CRC cases and 9,979 controls were available for the meta-analysis (Supplementary Figure 1).
The study was conducted in accordance with the declaration of Helsinki. Written informed consent 
was obtained from all subjects and the study was approved by respective ethical review boards at host 
institutions.
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Statistical and bioinformatic analysis. Analyses were undertaken using R(v3.02)24 and PLINK25 
software. The association between each SNP and the risk of CRC was assessed by the Cochran–Armitage 
trend test. ORs and associated 95% CIs were calculated by unconditional logistic regression. Phasing of 
GWAS SNP genotypes was performed using SHAPEIT(v2.644)26. Prediction of the untyped SNPs was 
carried out using IMPUTE(v2.3.0)27 based on the data from the 1000 Genomes Project (Phase 1 inte-
grated variant set, v3.20101123)28 as reference. Imputed data were analyzed using SNPTEST(v2.4.1)29. 
Association meta-analyses only included markers with info scores > 0.4, imputed call rates/SNP > 0.9 and 
MAFs > 0.01. The fidelity of imputation, as assessed by the concordance between imputed and sequenced 
SNPs, was examined in a subset of 200 UK cases. Meta-analyses were carried out using META(v2.4-1)30, 
under an inverse-weighted fixed-effects model using the genotype probabilities from IMPUTE, where a 
SNP was not directly typed. We calculated Cochran’s Q statistic to test for heterogeneity and the I2 sta-
tistic to quantify the proportion of the total variation that was caused by heterogeneity –I2 values ≥ 75% 
are considered characteristic of large heterogeneity31. Associations by sex, age and clinico-pathological 
phenotypes were examined by logistic regression in case-only analyses. The familial relative risk of CRC 
attributable to each variant was calculated as detailed by Pharoah et al.32 assuming the overall familial 
risk of CRC, as shown in epidemiological studies, is 2.233.
To explore epigenetic profiles of association signals, we used ChromHMM34. States were inferred 
from ENCODE Histone Modification data on the CRC cell line HCT116 (DNAse, H3K4me3, H3K4me1, 
H3K27ac, Pol2 and CTCF)35 binarized using a multivariate Hidden Markov Model.
To examine whether any of the SNPs or their proxies (i.e. r2 > 0.8 in 1000genomes CEU reference 
panel) annotate putative transcription factor binding/enhancer elements we used the CADD (combined 
annotation dependent depletion) web-server36. We assessed sequence conservation using: PhastCons 
(< 0.3 indicative of conservation), Genomic Evolutionary Rate Profiling37 (GERP) (− 12 to 6, with 6 
being indicative of complete conservation) and CADD (>10.0 deemed to be deleterious).
Analysis of TCGA data. To examine for a relationship between SNP genotype and mRNA expression 
we made use of Tumor Cancer Genome Atlas (TCGA)38 RNA-seq expression and Affymetrix 6.0 SNP 
data (dbGaP accession number: phs000178.v7.p6) on 223 colorectal adenocarcinoma (COAD) and 75 
rectal adenocarcinoma samples using a best proxy where SNPs were not represented directly. Association 
between normalised RNA counts per-gene and SNP genotype was quantified using the Kruskal-Wallis 
trend test. The frequency of somatic mutations in CRC was obtained using the CBioPortal for Cancer 
Genomics39,40 and TumorPortal web servers41.
Pathway analysis. To determine whether any genes mapping to the three newly identified regions 
act in pathways already over-represented in GWAS regions we utilized the NCI pathway interaction data-
base42. All genes within the LD block containing each tagSNP, or linked to the SNP through functional 
experiments (MYC) were submitted as a Batch query using the NCI-Nature curated data source.
Assignment of microsatellite instability (MSI), KRAS, NRAS and BRAF status in cancers. Tumour 
MSI status in CRCs was determined using the mononucleotide microsatellite loci BAT25 and BAT26, 
which are highly sensitive MSI markers. Samples showing more than or equal to five novel alleles, when 
compared with normal DNA, at either or both markers were assigned as MSI-H (corresponding to 
MSI-high)43.
Tumours from the COIN study were screened for mutations in KRAS codons 12, 13, and 61 and BRAF 
codon 600 by pyrosequencing18. Additionally, KRAS (all three codons), BRAF (codons 594 and 600), and 
NRAS (codons 12 and 61) were screened for mutations by MALDI-TOF mass array (Sequenom, San 
Diego, CA, USA)44.
Results
In the primary scan, 2,244 advanced (stage IV) CRC cases ascertained through the Medical Research 
Council (MRC) trials COIN18 and COIN-B45 were analysed with control data on 2,674 individuals from 
the WTCCC2 UK National Blood Service Control Group. After applying strict quality control criteria 
(Materials and Methods), we analysed 234,675 autosomal SNPs for association with CRC risk in 1,950 
cases and 2,162 controls. A Q–Q plot of observed versus expected χ2-test statistics showed little evidence 
for an inflation of test statistics, thereby excluding the possibility of substantive hidden population sub-
structure, cryptic relatedness among subjects or differential genotype calling (inflation factor λ = 1.05; 
Supplementary Figure 1).
We performed a meta-analysis of our primary scan data with five non-overlapping GWAS case-control 
series of Northern European ancestry, which have been previously reported (Supplementary Table 2). 
The adequacy of the case-control matching and possibility of differential genotyping of cases and controls 
was assessed using Q-Q plots of test statistics. λ GC values46 for the UK1, Scotland1, VQ58, CCFR1 and 
CCFR2 studies were 1.02, 1.01, 1.01, 1.02 and 1.03 respectively (Supplementary Figure 1). Any ethnic 
outliers or individuals identified as related were excluded (Supplementary Figure 2).
After quality control procedures, the six GWAS provided data on 7,577 CRC cases and 9,979 controls. 
To maximise the prospects of identifying novel risk variants, we imputed over 10 million variants using 
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1000 Genomes Project Pilot data as a reference panel. Q-Q plots for all variants post-imputation did 
not show evidence of substantive over-dispersion introduced by imputation (Supplementary Figure 1).
Meta-analysis. Associations for all 23 established European CRC risk SNPs showed a direction of 
effect consistent with previously reported studies, with eight of the loci having a P-value of < 5.0 × 10−8 
(Supplementary Table 3; Fig.  1). Additionally six SNPs previously identified in GWAS in Asian popu-
lations as determinants of CRC risk showed evidence for an association in this meta-analysis; albeit at 
varying degrees of significance (P-values ranging from 3.64 × 10−2 to 1.71 × 10−3; Supplementary Table 
3); thereby providing support for trans-ethnic effects.
Excluding SNPs (including those correlated with r2 > 0.8) mapping to the risk loci, five variants in dis-
tinct regions of linkage disequilibrium (LD) were associated with CRC at P < 1.0 × 10−7 (Table 1; Fig. 1).
We assessed the fidelity of imputation in 200 UK cases by comparing imputed genotypes with those 
obtained by sequencing. For the three common variants (MAF > 0.05), rs72647484, rs16941835 and 
Figure 1. Genome-wide P-values (–log10P, y-axis) plotted against their respective chromosomal 
positions (x-axis). Known regions attaining genome-wide significance (i.e. P = 5.0 × 10−8) are labelled with 
their chromosomal location. Variants in grey lie in novel regions that reach the significance threshold level 
(P = 1.0 × 10−7) required for variants to be analysed further in this study. Variants in black lie in novel 
regions attaining genome-wide significance.
Individual study P-values Meta-analysis
Locus
Nearest 
gene(s) SNP
Position 
(bps)
Al-
leles RAF INFO UK1 Scotland1 VQ58 CFR1 CFR2 COIN
OR 
(95% 
CI) P Phet
1p36.12 WNT4/CDC42 rs72647484 22,587,728 TC 0.91
0.94 
(0.85-
0.99)
3.25 × 10−2 3.32 × 10−5 4.99 × 10−2 4.08 × 10−2 4.58 × 10−2 3.47 × 10−2
1.24 
(1.15-
1.33)
1.21 × 10-8 0.33
5q15 ERAP1 rs202110856 96,129,872 GGC 0.99
0.79 
(0.66-
0.92)
2.97 × 10−1 5.96 × 10-8 2.81 × 10−2 4.43 × 10−1 3.35 × 10−1 3.67 × 10−1
1.51 
(1.23-
1.86)
6.67 × 10-8 0.13
10p13 CUBN rs10904849 16,997,266 GT 0.68
0.98 
(0.97-
1.00)
2.90 × 10−2 3.39 × 10−1 2.36 × 10−2 8.68 × 10−3 7.73 × 10−2 1.29 × 10−3
1.13 
(1.08-
1.19)
7.01× 10-8 0.83
16p13.2 C16orf72 rs79900961 9,297,812 GA 0.98
0.70 
(0.61-
0.74)
2.21 × 10−1 8.68 × 10−2 1.04 × 10−3 2.54 × 10−2 2.41 × 10−1 1.02 × 10−3
1.49 
(1.26-
1.76)
4.93 × 10-8 0.76
16q24.1 FOXL1 rs16941835 86,695,720 GC 0.21
0.97 
(0.92-
0.99)
1.04 × 10−1 1.17 × 10−1 1.57 × 10−4 3.74 × 10−3 1.25 × 10−2 3.65 × 10−1
1.16 
(1.09-
1.22)
5.06 × 10-8 0.40
Table 1.  Summary statistics for variants showing an association with CRC risk at P < 1.0 × 10−7. For each variant shown along with meta-analysis 
test statistics are the P-values from the six individual studies and imputation Information scores. Risk alleles are given in bold. INFO, imputation 
Information score; P-het, P-value of heterogeneity between studies; RAF, risk allele frequency.
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rs10904849 which each had imputation info scores > 0.9 there was high correlation between imputed 
and directly typed genotype (r2 = 0.98, 1.00 and 0.99, respectively). For the rare variant rs79900961 
(MAF = 0.016), the correlation was poor (r2 = 0.60). The call rate for the rare Indel on chromosome 5q15 
(rs202110856) in the sequencing data was only 71% and both imputed heterozygotes were sequenced as 
homozygous reference. Therefore, only the three common variants at 1p36.12, 10p13 and 16q24.1 were 
subject to further analyses.
In the combined analysis of the six GWAS datasets, rs72647484, which maps to chromosome 
1p36.12 (22,587,728 bps; NCBI build 37), showed the strongest evidence for association with CRC 
(P = 1.21 × 10−8; Phet = 0.33, I2 = 14%; Fig.  2a). rs72647484 maps within a 300 kb block of LD encom-
passing WNT4 (wingless-type mmtv integration site family, member 4; MIM 603490) and CDC42 (cell 
division cycle 42, MIM 116952; Fig. 3a). The second strongest association was provided by rs16941835 
(P = 5.06 × 10−8; Phet = 0.40, I2 = 3%; Fig.  2c) which localises to the long non-coding RNA (lncRNA) 
RP11-58A18.1 at chromosome 16q24.1 (86,659,720 bps; NCBI build 37) within a 65 kb region of LD 
(Fig. 3c). The nearest coding gene, ~500 kb away, is the transcription factor FOXL1. The third strongest 
association was provided by rs10904849 (P = 7.01 × 10−8; Phet = 0.83, I2 = 0%; Fig.  2b) which localises 
to chromosome 10p13 (16,997,266 bps; NCBI build 37) within intron 31 of the gene encoding cubulin 
(CUBN; alias intrinsic factor-cobalamin receptor [IFCR], MIM 602997; Fig. 3b).
Bioinformatic analysis of risk variants. To gain insight into the biological basis of the associa-
tions we analysed publicly available RNA-seq expression and SNP data from TCGA on 223 colonic and 
75 rectal cancers using rs10904850 and rs2744753 as proxies for rs10904849 (r2 = 0.97; D’ = 1.00) and 
rs72647484 (r2 = 0.64; D’ = 0.89) respectively. After adjustment for multiple testing, no significant asso-
ciations were seen between SNP genotype and expression of genes mapping to any of the three risk loci 
(Supplementary Table 4).
We examined whether any of the SNPs or their proxies (i.e. r2 > 0.8 in 1000 Genomes CEU reference 
panel) lie at putative transcription factor binding/enhancer elements and derived GERP and PhastCons 
scores to asses sequence conservation at these positions (Supplementary Table 5).
rs16941835 maps to a regulatory feature with histone modification suggestive of an enhancer element. 
rs10904852, in LD with rs10904849 (r2 = 0.95, D’ = 1.00) is conserved (GERP and PhastCons scores of 
1.20 and 0.47 respectively) with CADD score of 11.53. A moderate CADD score (8.21) was associated 
with rs7267484 (22,590,125 bps) which is strong LD with rs72647489 (r2 = 0.93, D’ = 1.00). Six proxy 
SNPs in LD with rs16941835 showed some evidence of transcription factor binding (Supplementary 
Table 5). We made use of TCGA data to examine the frequency of somatic mutation of CDC42, WNT4, 
FOXL1 or CUBN in CRC. None of these genes showed evidence of significant somatic mutation. Next, 
we conducted pathway analysis to determine whether any genes mapping to the three newly identified 
regions act in pathways already over-represented in GWAS. Pathways containing three or more genes are 
shown in Supplementary Table 6. While this analysis identifies the BMP-signalling pathway as expected, 
no catalogued pathways were discernible involving genes mapping to any of the newly identified regions.
It is increasingly recognized that some genetic variants can have pleiotropic effects, influencing the 
risk of more than one cancer type. To explore the possibility that rs72647484, rs10904849 or rs16941835 
affects the risk of other malignancies, we examined the association with lung cancer47, acute lympho-
blastic leukaemia48, multiple myeloma49, glioma50 and meningioma51 using data from previously reported 
GWASs. However, for these cancers, there was no evidence of rs72647484, rs10904849 or rs16941835 (or 
correlated SNP r2 ≥ 0.8) being associated with tumour risk (i.e. P > 0.05).
Finally, the relationship between clinico-pathological variables (sex, age at diagnosis, family history 
of CRC, tumour stage or microsatellite instability (MSI), KRAS-mutant status and BRAF-mutant status) 
and genotype at rs72647484, rs10904849 and rs16941835 was assessed by case-only logistic regression 
(Supplementary Table 7). There was evidence of a relationship between rs72647484 and KRAS-mutant 
status (P = 0.03) with the T risk allele associated with KRAS-mutant CRC; however this finding was not 
significant after accounting for multiple testing. None of the other SNPs showed any association with any 
of the clinico-pathological variables examined (i.e. P > 0.05).
Discussion
We have provided evidence supporting the existence of new susceptibility loci for CRC at 1p36.12, 10p13 
and 16q24.1. The 1p36.12 association implicates WNT4 and/or CDC42 as possible determinates of CRC 
risk. WNT4 is part of a family of structurally related genes that encode cysteine-rich secreted glycopro-
teins that act as extracellular signalling factors. WNT4, WNT14, and WNT16 may play redundant roles 
in signalling through the CTNNB1-mediated canonical Wnt-pathway52 which is known to play a central 
role in colorectal tumorigenesis. Additionally, WNT4 signalling appears to play a pivotal role during 
organogenesis, acting as an autoinducer of mesenchyme-to-epithelial transition. Inactivating germline 
mutations in WNT4 cause mullerian aplasia and hyperandrogenism (MIM 158330) and are responsible 
for the autosomal recessive SERKAL syndrome (Sex Reversal and Kidney, Adrenal, and Lung dysgen-
esis; MIM 611812). A priori dysfunction of either WNT4 or CDC42 could be the biological basis for 
the 1p36.12 association. Cdc42 is a Ras-related GTP-binding protein with roles in establishment of cell 
polarity, regulation of cell morphology, motility, and cell cycle progression in mammalian cells, and 
malignant transformation53. Notably, Cdc42 regulates the actin cytoskeleton through activation of WASP 
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proteins and cell polarity through GSK3-beta and APC. Rho-GTPase signalling has a documented role in 
the development of CRC54. Activation of Rho GTPase Cdc42 promotes adhesion and invasion in CRC55 
and targeting Cdc42 with AZA197 suppresses primary colon cancer growth and prolongs survival in a 
xenograft model through down regulation of PAK156.
Since rs10904849 is intronic to CUBN and the region of LD does not encompass any other genes 
or transcripts, there is a high likelihood that the functional basis of the 10p13 association is mediated 
Figure 2. Forest plot of the odds ratios for the association between rs72647484, rs16941835, rs10904849 
and CRC. Studies were weighted according to the inverse of the variance of the log of the OR calculated 
by unconditional logistic regression. Horizontal lines: 95% confidence intervals (95% CI). Box: OR point 
estimate; its area is proportional to the weight of the study. Diamond (and broken line): overall summary 
estimate, with confidence interval given by its width. Unbroken vertical line: null value (OR = 1.0).
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Figure 3. Regional plot of association results and recombination rates for the (a) 1p36.12, (b) 10p13 
and (c) 16q24.1 risk loci. Association results of both genotyped (triangles) and imputed (circles) SNPs in 
the GWAS samples and recombination rates within the loci at 1p36.12 (a), 10p13 (b) and 16q24 (c). For 
each plot, − log10 P values (y axis) of the SNPs are shown according to their chromosomal positions (x axis). 
The top imputed SNP in each combined analysis is shown as a large triangle and is labelled by its rsID. The 
colour intensity of each symbol reflects the extent of LD with the top SNP: white (r2 = 0) through to dark 
red (r2 = 1.0), with r2 estimated from the 1000 Genomes Phase 1 data. Genetic recombination rates (cM/
Mb), are shown with a light blue line. Physical positions are based on NCBI build 37 of the human genome. 
Also shown are the relative positions of genes and transcripts mapping to each region of association. The 
lower panel shows the chromatin state segmentation track (ChromHMM).
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through CUBN. Cubilin is the intestinal receptor for the endocytosis of intrinsic factor-vitamin B12 and a 
receptor in epithelial apoA-I/HDL metabolism57. Additionally cubilin is an important co-receptor in the 
endocytic pathway for retrieval of 25(OH)D3-DBP complexes by megalin-mediated endocytosis in the 
kidney58. Germline mutations in CUBN cause recessive megaloblastic anemia-1 (MGA1; MIM 261100). 
It is conceivable that common genetic variance in CUBN, while being insufficient to cause a “MGA type 
phenotype” would have physiological effects by virtue of long term effect on the cellular bioavailability 
of B12. Although it is entirely speculative, as epidemiological studies have yet to convincingly establish 
levels of B12 as a risk factor for CRC59,60, its role in DNA biosynthesis makes genetically determined 
variation in B12 availability a plausible candidate for a role in the development of CRC.
LncRNAs are regulators of transcription and are increasingly recognised as playing a role in cancer 
biology. While there is currently no evidence to implicate the RP11-58A18.1 lncRNA in CRC, lncRNAs 
CCAT1 and CCAT2 probably do play such roles61,62, and it is entirely plausible that the impact of varia-
tion at 16q24.1 on risk is mediated through similar long range effects.
One of the reasons for the failure to identify these CRC-loci previously is that, in addition to the 
issue of study power, they were not optimally tagged by SNPs featured on many commercial arrays. The 
power of our study to detect the major common loci conferring risks of 1.2 or greater (such as the 18q24 
variant) was high. Hence, it is very unlikely there are additional CRC SNPs with similar effects for alleles 
with frequencies > 0.2 in populations of European ancestry.
In this study, we have only considered SNPs showing evidence of an association with a stipulated 
P-value threshold of < 1 × 10−7. There exist, however, many variants with P-values just above this thresh-
old which may also warrant investigation in a further study (Fig.  1). Hence further efforts to expand 
the scale of GWAS meta-analyses, in terms of both sample size and SNP coverage, and to increase the 
number of SNPs taken forward to large-scale replication, may identify additional variants for CRC.
In conclusion, we have provided evidence for 3 new susceptibility loci for CRC. Our data also provide 
further evidence for the value of meta-analysis and the value of imputation as a means of enhancing the 
detection of novel risk loci thereby extending the utility of GWAS data.
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